Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News OKYO Pharma Ltd OKYO

Healthcare Biotechnology
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to... see more

Current News (NDAQ:OKYO)

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

GlobeNewswire 9 days ago

OKYO Pharma Announces Successful Type C Meeting with the FDA

GlobeNewswire 11 days ago

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

GlobeNewswire January 23, 2026

OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

GlobeNewswire January 5, 2026

OKYO Pharma to Ring the Opening Bell at Nasdaq

GlobeNewswire December 19, 2025

OKYO Pharma Announces Chairman and Founder Acquires Shares

GlobeNewswire December 15, 2025

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

GlobeNewswire December 11, 2025

OKYO Pharma Announces Chairman and Founder Acquires Shares

GlobeNewswire December 3, 2025

OKYO Pharma Announces Chairman and Founder Acquires Shares

GlobeNewswire November 21, 2025
View More News ››

Opinion & Analysis (NDAQ:OKYO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OKYO)

BUY BUY BUY BUY BUY

All in all good over all
Nibinator - July 11, 2024
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc., together with its subsidiaries, engages in the design, engineering, manufacture, testing, and distribution of ...
View More »

Podcasts